2025
Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss
Fu W, Chen M, Wang K, Chen Y, Cui Y, Xie Y, Lei Z, Hu W, Sun G, Huang G, He C, Fretz J, Hettinghouse A, Liu R, Cai X, Zhang M, Chen Y, Jiang N, He M, Wiznia D, Xu H, Chen Z, Chen L, Tang K, Zhou H, Liu C. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Cell Research 2025, 35: 23-44. PMID: 39743632, PMCID: PMC11701132, DOI: 10.1038/s41422-024-01016-0.Peer-Reviewed Original ResearchConceptsGC-induced osteoporosisBone lossInflammatory arthritisAdverse effects of dexamethasoneGlucocorticoid-induced bone lossHigh-dose dexamethasoneEffect of dexamethasoneFDA-approved drug librarySynthetic GCTreat inflammatory arthritisImmunosuppressive drugsPrescribed anti-inflammatoryGC receptorCombinatorial administrationSide effectsLow affinityGlucocorticoidOsteoporosisDexamethasoneReceptorsAdverse effectsBinding receptorsAnti-inflammatoryDrug libraryTau deficiency
2020
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Schultze A, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Bacon S, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Mathur R, Drysdale H, Wong AYS, McDonald HI, Cockburn J, Forbes H, Parry J, Hester F, Harper S, Smeeth L, Douglas IJ, Dixon WG, Evans SJW, Tomlinson L, Goldacre B. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology 2020, 3: e19-e27. PMID: 33349815, PMCID: PMC7745258, DOI: 10.1016/s2665-9913(20)30378-7.Peer-Reviewed Original ResearchCOVID-19 mortalitySystemic lupus erythematosusPopulation-based cohort studyLupus erythematosusRheumatoid arthritisOpenSAFELY platformCohort studyImmunosuppressive drugsRheumatological diseasesSevere acute respiratory syndrome coronavirus 2National primary care dataAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Effectiveness of hydroxychloroquinePre-exposure usePrimary care dataSyndrome coronavirus 2COVID-19 outbreakCumulative COVID-19 mortalityCOVID-19Medical Research CouncilNegative control outcomesCOVID-19 deathsHydroxychloroquine useCox regression
2019
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugsImmunoadsorption in nephrotic syndrome: Where are we now and where are we going from here?
Kronbichler A, Gauckler P, Lee K, Shin J, Malvezzi P, Mayer G. Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here? Atherosclerosis Plus 2019, 40: 55-60. PMID: 31447217, DOI: 10.1016/j.atherosclerosissup.2019.08.027.Peer-Reviewed Original ResearchConceptsIdiopathic nephrotic syndromeFocal segmental glomerulosclerosisPlasma exchangeMembranous nephropathyNephrotic syndromeKidney transplantationManagement of idiopathic nephrotic syndromeThrombospondin type-1 domain-containing 7AClinical trialsPrimary focal segmental glomerulosclerosisPhase II clinical trialPhospholipase A2 receptorTreatment-resistant casesAbsence of genetic testingII clinical trialsTreatment formsPrescribed immunosuppressive drugsRemission ratePLA2R-AbPrimary MNImmunosuppressive drugsLDL apheresisA2 receptorsSafety profileTreatment optionsPersistence of Babesia microti Infection in Humans
Bloch EM, Kumar S, Krause PJ. Persistence of Babesia microti Infection in Humans. Pathogens 2019, 8: 102. PMID: 31319461, PMCID: PMC6789900, DOI: 10.3390/pathogens8030102.Peer-Reviewed Original ResearchTransfusion-transmitted babesiosisBabesia microti infectionBlood donor screeningImmune evasive strategiesPeripheral blood smearFifth of casesHost immune mechanismsNovel therapeutic measuresNovel preventive approachesHIV/AIDSTick-borne diseaseRed blood cellsSevere complicationsAnti-parasitic drugsBlood transfusionImmunocompetent individualsImmunosuppressive drugsDonor screeningMicroti infectionImmune mechanismsBlood donorsHealth burdenImmunoglobulin preparationsNew anti-parasitic drugsTherapeutic measures
2018
Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians
Lee K, Kronbichler A, Eisenhut M, Lee K, Shin J. Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. Autoimmunity Reviews 2018, 17: 201-214. PMID: 29353099, DOI: 10.1016/j.autrev.2017.12.001.Peer-Reviewed Original ResearchConceptsCardiovascular involvementRheumatic diseasesTreating physicianRisk factorsTraditional cardiovascular risk factorsSystemic autoimmune diseaseSystemic rheumatic diseasesCardiovascular risk factorsPotential adverse eventsDisease-specific factorsImmunosuppressive agentsImmunosuppressive drugsPremature atherosclerosisAdverse eventsHeart failureAutoimmune diseasesChronic inflammationCardioprotective efficacyInflammatory activityCardiac vesselsEarly diagnosisOptimal managementIntensive treatmentIncreased MortalityConduction system
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs
2013
Assessing the Effect of Immunosuppression on Engraftment of Pancreatic Islets
Vallabhajosyula P, Hirakata A, Shimizu A, Okumi M, Tchipashvili V, Hong H, Yamada K, Sachs DH. Assessing the Effect of Immunosuppression on Engraftment of Pancreatic Islets. Transplantation 2013, 96: 372-378. PMID: 23883972, PMCID: PMC3786704, DOI: 10.1097/tp.0b013e31829f7515.Peer-Reviewed Original ResearchConceptsTriple-drug immunosuppressionIslet functionAllogeneic islet cell transplantationExperimental animalsLong-term islet functionTriple-drug immunosuppressive regimenIntravenous glucose tolerance testEquivalent glycemic controlEffect of immunosuppressionGlucose tolerance testNormal glucose regulationIslet cell transplantationVivo large animal modelLong-term functionIslet equivalents/Large animal modelImmunosuppressive regimenIslet doseImmunologic factorsRecipient weightEngrafted isletsGlycemic controlMinor histocompatibilityImmunosuppressive drugsCell transplantation
2012
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Birdwell K, Grady B, Choi L, Xu H, Bian A, Denny J, Jiang M, Vranic G, Basford M, Cowan J, Richardson D, Robinson M, Ikizler T, Ritchie M, Stein C, Haas D. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics And Genomics 2012, 22: 32-42. PMID: 22108237, PMCID: PMC3237759, DOI: 10.1097/fpc.0b013e32834e1641.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Body WeightCytochrome P-450 CYP3ADatabases, Nucleic AcidDose-Response Relationship, DrugDrug MonitoringElectronic Health RecordsFemaleGenetic Association StudiesGenotypeHemoglobinsHumansImmunosuppressive AgentsKidney TransplantationLinkage DisequilibriumMaleMiddle AgedPolymorphism, Single NucleotidePregnane X ReceptorReceptors, SteroidTacrolimusConceptsTacrolimus dose requirementsKidney transplant recipientsDose requirementsElectronic medical recordsBlood concentrationsTransplant recipientsMedical recordsCYP3A5 rs776746Electronic medical record dataInterindividual pharmacokinetic variabilityTacrolimus blood concentrationsNarrow therapeutic indexDNA biobanksMedical record dataTherapeutic drug monitoringDrug-metabolizing enzymesKidney transplantationClinical factorsPrimary outcomeImmunosuppressive drugsPharmacokinetic variabilityTacrolimus clearanceClinical covariatesPharmacogenomic predictorsTherapeutic index
2011
Dissecting the Immune Cell Mayhem That Drives Lupus Pathogenesis
Craft JE. Dissecting the Immune Cell Mayhem That Drives Lupus Pathogenesis. Science Translational Medicine 2011, 3: 73ps9. PMID: 21389262, PMCID: PMC3694130, DOI: 10.1126/scitranslmed.3002138.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusPathogenesis of SLEAutoimmune disease systemic lupus erythematosusDisease systemic lupus erythematosusSerious side effectsScience Translational MedicineLupus pathogenesisLupus erythematosusImmunosuppressive drugsCombination therapyCommon treatmentSide effectsImmune systemPathogenesisTherapyTranslational medicineErythematosusInflammationInterferonNeutrophils
2009
Update on Babesiosis
Vannier E, Krause PJ. Update on Babesiosis. Interdisciplinary Perspectives On Infectious Diseases 2009, 2009: 984568. PMID: 19727410, PMCID: PMC2734943, DOI: 10.1155/2009/984568.Peer-Reviewed Original ResearchTick-borne infectious diseaseHuman babesiosisBlood safety riskSpecific antimicrobial therapyMultiple prevention strategiesFulminant diseaseThin blood smearsClinical featuresExchange transfusionModerate illnessImmunosuppressive drugsAsymptomatic infectionDefinitive diagnosisAsymptomatic carriersAntimicrobial therapyConvalescent seraSevere diseaseImmunocompromised individualsHigh riskSevere casesEndemic areasPrevention strategiesBabesia antibodiesHealthy adultsInfection rangeLupus immunotherapy using CD4 targeted nanoparticles (48.29)
Look M, Stern E, Wang Q, DiPlacido L, Craft J, Fahmy T. Lupus immunotherapy using CD4 targeted nanoparticles (48.29). The Journal Of Immunology 2009, 182: 48.29-48.29. DOI: 10.4049/jimmunol.182.supp.48.29.Peer-Reviewed Original ResearchNZB/W F1 miceW F1 miceCD4 T cellsImmunosuppressive drugsDisease progressionF1 miceT cellsImmunosuppressive drug dosageSystemic lupus erythematosusNanoparticle therapyConventional therapeutic regimensFrequency of dosageLupus erythematosusAutoantibody productionTherapeutic regimensWeekly treatmentTherapeutic featuresAnimal modelsB cellsDrug dosageTherapeutic efficacyLupusImmunotherapyTherapyMice
2007
Alloimmune-Mediated Vascular Remodeling of Human Coronary Artery Grafts in Immunodeficient Mouse Recipients Is Independent of Preexisting Atherosclerosis
Wang Y, Ahmad U, Yi T, Zhao L, Lorber MI, Pober JS, Tellides G. Alloimmune-Mediated Vascular Remodeling of Human Coronary Artery Grafts in Immunodeficient Mouse Recipients Is Independent of Preexisting Atherosclerosis. Transplantation 2007, 83: 1501-1505. PMID: 17565324, DOI: 10.1097/01.tp.0000264560.51845.67.Peer-Reviewed Original ResearchConceptsImmunodeficient mouse recipientsHuman coronary artery graftsCoronary artery graftsVascular remodelingArtery graftCoronary atherosclerosisMouse recipientsAllogeneic human peripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsPeripheral blood mononuclear cellsBlood mononuclear cellsArterial injuryGraft arteriosclerosisIntimal injuryLuminal lossImmunosuppressive drugsLumen lossMononuclear cellsIntimal thickeningClinical studiesIntimal expansionAtherosclerotic lesionsOrgan donorsChimeric modelAtherosclerosis
2006
Uso do rituximabe para o tratamento da plaquetopenia do lúpus eritematoso sistêmico: eficácia clínica e efeito nas moléculas de co-estimulação
Santiago M, Reis E, Lima I, Reis M. Uso do rituximabe para o tratamento da plaquetopenia do lúpus eritematoso sistêmico: eficácia clínica e efeito nas moléculas de co-estimulação. Revista Brasileira De Reumatologia 2006, 46: 153-156. DOI: 10.1590/s0482-50042006000200013.Peer-Reviewed Original ResearchSystemic lupus erythematosusCases of SLEInfusions of rituximabUse of prednisoneUse of corticosteroidsLúpus eritematoso sistêmicoIntravenous immunoglobulinSLE patientsRare complicationLupus erythematosusImmunosuppressive drugsPersistent thrombocytopeniaCostimulatory moleculesPeripheral bloodSide effectsB cellsRituximabThrombocytopeniaCytometry analysisPatientsInfusionAzathioprineCorticosteroidsErythematosusPrednisone
2003
Infectious complications in SLE after immunosuppressive therapies
Kang I, Park S. Infectious complications in SLE after immunosuppressive therapies. Current Opinion In Internal Medicine 2003, 2: 629-635. DOI: 10.1097/00132980-200302060-00015.Peer-Reviewed Original ResearchSystemic lupus erythematosusMannose-binding lectin variant allelesHigh-dose glucocorticoidsImmunosuppressive therapyLupus erythematosusInfectious complicationsMycophenolate mofetilImmunosuppressive drugsRisk factorsVariant allelesMannose-binding lectin deficiencyMajor organ involvementUse of steroidsCommon viral infectionsExtrinsic risk factorsStrong risk factorIncidence of infectionHerpes zosterOrgan involvementSerious infectionsLectin deficiencyErythematosusImmune responsePatientsViral infectionInfectious complications in SLE after immunosuppressive therapies
Kang I, Park S. Infectious complications in SLE after immunosuppressive therapies. Current Opinion In Internal Medicine 2003, 2: 629-635. DOI: 10.1097/00132980-200312000-00015.Peer-Reviewed Original ResearchSystemic lupus erythematosusMannose-binding lectin variant allelesHigh-dose glucocorticoidsImmunosuppressive therapyLupus erythematosusInfectious complicationsMycophenolate mofetilImmunosuppressive drugsRisk factorsVariant allelesMannose-binding lectin deficiencyMajor organ involvementUse of steroidsCommon viral infectionsExtrinsic risk factorsStrong risk factorIncidence of infectionHerpes zosterOrgan involvementSerious infectionsLectin deficiencyErythematosusImmune responsePatientsViral infection
2002
Babesiosis
Krause PJ. Babesiosis. 2002, 86: 361-373. PMID: 11982307, DOI: 10.1016/s0025-7125(03)00092-0.Peer-Reviewed Original ResearchConceptsAge 50 yearsFlulike illnessThin blood smearsHIV infectionHospital admissionExchange transfusionAsplenic individualsImmunosuppressive drugsPolymerase chain reactionSevere casesSpecific diagnosisFatal diseaseBlood smearsProtozoal parasitesGreater riskLyme diseaseSpecific antibodiesChain reactionTransmits Lyme diseaseInfectionDiseaseBabesiosisSame tickNorthern midwestern United StatesMost cases
1994
The benefit of early treatment with immunosuppressive agents in lupus nephritis.
Esdaile J, Joseph L, MacKenzie T, Kashgarian M, Hayslett J. The benefit of early treatment with immunosuppressive agents in lupus nephritis. The Journal Of Rheumatology 1994, 21: 2046-51. PMID: 7869308.Peer-Reviewed Original ResearchConceptsHour urinary protein excretionUrinary protein excretionLead-time biasRenal biopsyLupus nephritisRenal insufficiencyRenal involvementSerum creatinineProtein excretionImmunosuppressive agentsEarly treatmentHigh-dose prednisoneLupus renal involvementSubsequent renal insufficiencyTime biasFirst renal biopsySelection biasDose prednisoneTubulointerstitial indexRenal diseaseLongterm prognosisImmunosuppressive drugsEffect of durationBiopsySignificant association
1989
Catatonic syndrome caused by autoimmune disease: spontaneous remission.
Lichtenstein A, Calish I, Oliveira R, Miguel Filho E, Rocha A. Catatonic syndrome caused by autoimmune disease: spontaneous remission. Clinics 1989, 44: 312-5. PMID: 2486424.Peer-Reviewed Original ResearchConceptsCSF immune complexesAutoimmune diseasesImmune complexesCatatonic syndromeCerebrospinal fluidPositive antinuclear factorSystemic lupus erythematosusAntinuclear factorLupus erythematosusRare manifestationSystemic involvementSystemic manifestationsSpontaneous remissionImmunosuppressive drugsPsychiatric manifestationsCatatonic patientsImmunologic testsCase reportMetabolic disturbancesPsychiatric effectsNucleolar patternSchizophrenic disordersValuable markerDiseasePsychiatric picture
1985
EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION
Bia M, Andiman W, Gaudio K, Kliger A, Siegel N, Smith D, Flye W. EFFECT OF TREATMENT WITH CYCLOSPORINE VERSUS AZATHIOPRINE ON INCIDENCE AND SEVERITY OF CYTOMEGALOVIRUS INFECTION POSTTRANSPLANTATION. Transplantation 1985, 40: 610-614. PMID: 3000031, DOI: 10.1097/00007890-198512000-00007.Peer-Reviewed Original ResearchConceptsAntithymocyte globulinSteroid-resistant rejectionRenal transplant patientsCMV infectionAzathioprine groupCMV diseaseTransplant patientsEffect of ATGUse of ATGAzathioprine-treated patientsCMV antibody titersCyclosporine-treated patientsNumber of patientsCulture of urineEffect of treatmentATG therapyCadaveric recipientsInfection posttransplantationAdditional therapyCytomegalovirus infectionDrug regimensImmunosuppressive drugsAntibody titersAzathioprinePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply